Atea Pharmaceuticals Reports First Quarter 2022 Financial Re

10.05.2022 - New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo (p=0.047, unadjusted, exploratory) New clinical ...

Related Keywords

United States , Boston , Massachusetts , Jean Pierre Sommadossi , Jonae Barnes , Founder Of Atea Pharmaceuticals , Bemnifosbuvir Clinical Development , Nature Communications , Drug Administration , Program Update For Dengue , Nasdaq , See The Company , Development Expenses , Atea Pharmaceuticals , Combination Program , Corporate Communications , Atea Pharmaceuticals Inc , Risk Assessment Specialty Selection Executive Committee , Executive Officer , Program Update , Topline Efficacy Results , Final Analysis , High Risk Patients , Vitro Results , Bemnifosbuvir Mechanism Data , Peer Reviewed Journal , Bemnifosbuvir Toxicology Data , Annual Meeting , Fever Study , Human Challenge Trial , Cash Equivalents , Administrative Expenses , Consolidated Statement , Comprehensive Income , Quarterly Report , Investor Events , Private Securities Litigation Reform Act , Annual Report , Investor Relations ,